Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 9/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | DBH | P09172 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144368 | 0.87 | KMT2A (0.47) | MEN1KMT2ALMNASLC29A1ADORA2A | |
| SCHEMBL29853379 | 0.80 | MEN1 (0.58) | MEN1KMT2ALMNASLC29A1ADORA2A | |
| SCHEMBL946430 | 0.80 | MEN1 (0.58) | MEN1KMT2ALMNASLC29A1ADORA2A | |
| SCHEMBL183167 | 0.79 | YTHDC1 (0.47) | KMT2AADORA2A | |
| SCHEMBL29601245 | 0.79 | YTHDC1 (0.47) | KMT2AADORA2A | |
| SCHEMBL21883488 | 0.77 | CYP11B1 (0.50) | KMT2A | |
| SCHEMBL30496448 | 0.77 | CYP11B1 (0.50) | KMT2A | |
| SCHEMBL6900306 | 0.76 | MET (0.47) | MEN1KMT2ALMNAADORA2AKDM4E | |
| SCHEMBL30020920 | 0.76 | MET (0.47) | MEN1KMT2ALMNAADORA2AKDM4E | |
| SCHEMBL15921469 | 0.76 | P2RX7 (0.40) | ADORA2AADORA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3997089-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | University Of Virginia Patent Foundation (US) | 2022-05-18 | — | — | EP | claimed |
| US-20220251085-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3997089-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | University Of Virginia Patent Foundation (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251085-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | DDB1, HSPBP1, ATIC | MEN1 4854/4885KMT2A 4554/4885LMNA 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.